New drug shows promise for sustained weight loss in type 2 diabetes

NCT ID NCT07684144

Not yet recruiting Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests a drug called maridebart cafraglutide (MariTide) in people who are overweight or obese and also have type 2 diabetes. The goal is to see if the drug can help with long-term weight loss and blood sugar control, and to check its safety over time. Participants receive either the drug or a placebo as an injection under the skin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maridebart cafraglutide (MariTide)
What this could lead to: If successful, this could provide a new long-term treatment option for weight loss and blood sugar control in people with obesity and type 2 diabetes.
What could go wrong: This is an extension trial, so results depend on earlier findings. Side effects may occur, and the drug may not work for everyone or may lose effectiveness over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.